Checkpoint fight at the Alamo in San Antonio? Say it ain’t so!
This is the $64M question that will be on many people’s mind after seeing two SABCS headlines today:
“Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancerwith Lymph Node Involvement.”
“Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer.”
In order to answer the question fairly, there are plenty of critical points we can look at in order to address it.
That’s the topic of today’s post in a nutshell… and yes, we do come to a firm conclusion.
Curious to find out more about the latest breast cancer data and get a heads up on additional insights from our SABCS commentary?Subscribers can log-in or you can click to gain access to BSB Premium Content.
ESMO18 is rapidly approaching with only a week to go before the conference kicks off in Munich this year.
So far in our Preview series we have highlighted what to watch out for in the late breakers, neoantigens, as well as the oral talks and poster discussions.
Now it’s time to turn our focus on the nuggets or gems that can be gleaned from the poster halls – there’s always a few pleasant surprises in store. There are small and large pharma/biotech companies included in this latest list on a wide range of therapeutics and tumour types.
There are also some interesting emerging trends, as well as hints of what might happen with some future phase 3 readouts that could catch a few people by surprise.
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.